Join
Live feed
·
PRReleasevia Quantisnow
Protagonist Therapeutics Inc. logo

Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

ByQuantisnow·Wall Street's wire, on your screen.
PTGX· Protagonist Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTGX (Protagonist Therapeutics Inc.) and more on Quantisnow.